Protara Therapeutics (TARA) Capital Expenditures (2013 - 2025)

Protara Therapeutics (TARA) has reported Capital Expenditures for 13 consecutive years, with $24000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Capital Expenditures changed N/A year-over-year to $24000.0; the TTM figure through Dec 2025 stood at $94000.0 (up 108.89% YoY), while the FY2025 annual figure was $94000.0, up 49.21% from the prior year.
• Capital Expenditures grew to $24000.0 in Q4 2025 per TARA's latest filing, from $4000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $326000.0 in Q2 2021 and bottomed at -$64000.0 in Q3 2021.
• Historically, Capital Expenditures has averaged $53937.5 across 5 years, with a median of $21000.0 in 2022.
• Annual changes were most pronounced in 2021 — Capital Expenditures soared 5533.33% — and 2022, when it tumbled 96.21%.
• Protara Therapeutics' Capital Expenditures stood at $44000.0 in 2021, then sank by 86.36% to $6000.0 in 2022, then surged by 516.67% to $37000.0 in 2023, then sank by 78.38% to $8000.0 in 2024, then surged by 200.0% to $24000.0 in 2025.
• Business Quant data shows TARA's Capital Expenditures at $24000.0 in Q4 2025, $4000.0 in Q3 2025, and $22000.0 in Q2 2025.